DE69912760T2 - Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln - Google Patents
Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln Download PDFInfo
- Publication number
- DE69912760T2 DE69912760T2 DE69912760T DE69912760T DE69912760T2 DE 69912760 T2 DE69912760 T2 DE 69912760T2 DE 69912760 T DE69912760 T DE 69912760T DE 69912760 T DE69912760 T DE 69912760T DE 69912760 T2 DE69912760 T2 DE 69912760T2
- Authority
- DE
- Germany
- Prior art keywords
- use according
- oil
- cream
- galactolipid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000463 material Substances 0.000 title claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims abstract description 17
- 239000013543 active substance Substances 0.000 title claims abstract description 10
- 239000000839 emulsion Substances 0.000 title description 15
- 239000003795 chemical substances by application Substances 0.000 title description 5
- 230000005923 long-lasting effect Effects 0.000 title description 2
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 31
- 239000008346 aqueous phase Substances 0.000 claims abstract description 19
- 239000006071 cream Substances 0.000 claims description 63
- 239000003921 oil Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 19
- 239000006210 lotion Substances 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 14
- 230000000699 topical effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 239000007764 o/w emulsion Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 6
- 229940100611 topical cream Drugs 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 239000004909 Moisturizer Substances 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 5
- 230000001333 moisturizer Effects 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- KJXHHTPQSFDEKB-ZKMIVQISSA-N (9z,12e)-13-hydroxyoctadeca-9,12-dienoic acid Chemical compound CCCCC\C(O)=C/C\C=C/CCCCCCCC(O)=O KJXHHTPQSFDEKB-ZKMIVQISSA-N 0.000 claims description 3
- 229940030999 antipsoriatics Drugs 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 229940100617 topical lotion Drugs 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 235000019198 oils Nutrition 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 26
- 239000012071 phase Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 17
- 230000003020 moisturizing effect Effects 0.000 description 15
- 206010013786 Dry skin Diseases 0.000 description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 10
- 230000037336 dry skin Effects 0.000 description 10
- KDYAPQVYJXUQNY-OPHDRXFHSA-N 1,2-di-(alpha-linolenoyl)-3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-sn-glycerol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDYAPQVYJXUQNY-OPHDRXFHSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001486234 Sciota Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- -1 des Steroids Chemical class 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000009499 grossing Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010040954 Skin wrinkling Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- HNICUWMFWZBIFP-KDFHGORWSA-N alpha-Artemisic acid Chemical compound CCCCCC(O)\C=C\C=C\CCCCCCCC(O)=O HNICUWMFWZBIFP-KDFHGORWSA-N 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241001295925 Gegenes Species 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000245063 Primula Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QZXMUPATKGLZAP-DXLAUQRQSA-N [(2S)-1-hexadecanoyloxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QZXMUPATKGLZAP-DXLAUQRQSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011250 protective ointment Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9800729A SE9800729L (sv) | 1998-03-06 | 1998-03-06 | Ny topikal formulering I |
| SE9800729 | 1998-03-06 | ||
| PCT/SE1999/000347 WO1999044585A1 (en) | 1998-03-06 | 1999-03-08 | Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69912760D1 DE69912760D1 (de) | 2003-12-18 |
| DE69912760T2 true DE69912760T2 (de) | 2004-09-30 |
Family
ID=20410443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69912760T Expired - Lifetime DE69912760T2 (de) | 1998-03-06 | 1999-03-08 | Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1069886B1 (https=) |
| JP (1) | JP2002505272A (https=) |
| AT (1) | ATE253895T1 (https=) |
| AU (1) | AU750526B2 (https=) |
| CA (1) | CA2322850A1 (https=) |
| DE (1) | DE69912760T2 (https=) |
| DK (1) | DK1069886T3 (https=) |
| ES (1) | ES2211062T3 (https=) |
| NZ (1) | NZ506756A (https=) |
| PT (1) | PT1069886E (https=) |
| SE (1) | SE9800729L (https=) |
| WO (1) | WO1999044585A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005023640A1 (de) * | 2005-05-19 | 2006-11-23 | Beiersdorf Ag | Wirkstoffkombinationen aus Glucosylglyceriden und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und / oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304906A1 (en) | 2000-04-07 | 2001-10-07 | 1411198 Ontario Limited | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| EP1151745A1 (fr) * | 2000-05-05 | 2001-11-07 | L'oreal | Composition sous forme d'émulsion eau-dans-huile et ses utilisations cosmétiques |
| US20020165286A1 (en) * | 2000-12-08 | 2002-11-07 | Hanne Hedeman | Dermal anti-inflammatory composition |
| JP2005535642A (ja) | 2002-06-28 | 2005-11-24 | ニトロメッド インコーポレーティッド | オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法 |
| AU2005279704B2 (en) | 2004-08-31 | 2010-05-13 | Stiefel Research Australia Pty Ltd | Microemulsion and sub-micron emulsion process and compositions |
| US8449867B2 (en) | 2004-08-31 | 2013-05-28 | Stiefel Research Australia Pty Ltd | Microemulsion and sub-micron emulsion process and compositions |
| JP2008531045A (ja) * | 2005-03-04 | 2008-08-14 | ディーエスエム アイピー アセッツ ビー．ブイ． | 食品用微粒子状脂質組成物 |
| WO2007032727A1 (en) * | 2005-09-16 | 2007-03-22 | Dsm Ip Assets B.V. | Particulate lipid pharmaceutical composition |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| WO2008084253A1 (en) * | 2007-01-12 | 2008-07-17 | Lipopeptide Ab | Use of a galactolipid for wound and ulcer healing |
| US20100136124A1 (en) * | 2007-04-20 | 2010-06-03 | University Of South Australia | Nanoparticle-coated capsule formulation for dermal drug delivery |
| NZ599933A (en) | 2009-11-03 | 2014-08-29 | Lipidor Ab | Lipid layer forming composition for administration onto a surface of a living organism |
| US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
| US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| SG11201701292XA (en) * | 2014-08-27 | 2017-03-30 | Abbvie Inc | Topical formulation |
| PT3297605T (pt) | 2015-05-21 | 2022-05-30 | Dermavant Sciences GmbH | Composições farmacêuticas tópicas |
| US11617724B2 (en) | 2015-05-21 | 2023-04-04 | Dermavant Sciences GmbH | Topical pharmaceutical compositions |
| JP6997624B2 (ja) | 2015-06-18 | 2022-01-17 | ボシュ ヘルス ユーエス，エルエルシー． | 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物 |
| US11311482B2 (en) | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS597118A (ja) * | 1982-06-16 | 1984-01-14 | ユニリ−バ−・ナ−ムロ−ゼ・ベンノ−トシヤ−プ | 化粧用組成物 |
| JPS649908A (en) * | 1987-07-02 | 1989-01-13 | Kao Corp | Cosmetic, cosmetic set and make-up method |
| JPH0374316A (ja) * | 1989-08-11 | 1991-03-28 | Kanebo Ltd | 保湿剤 |
| JPH0818948B2 (ja) * | 1990-08-31 | 1996-02-28 | 花王株式会社 | 水性化粧料及びその製造法 |
| JPH0543465A (ja) * | 1991-08-08 | 1993-02-23 | Mitsubishi Kasei Corp | コルチコステロイド含有ローシヨン剤 |
| JPH069365A (ja) * | 1992-06-25 | 1994-01-18 | Kanebo Ltd | 皮膚化粧料 |
| AU683459B2 (en) * | 1993-03-12 | 1997-11-13 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| FR2710854B1 (fr) * | 1993-10-08 | 1995-12-01 | Oreal | Emulsion huile-dans-eau utilisable pour l'obtention d'une crème. |
| WO1995020943A1 (en) * | 1994-02-04 | 1995-08-10 | Scotia Lipidteknik Ab | Oil-in-water emulsions |
| SE9402453D0 (sv) * | 1994-07-12 | 1994-07-12 | Astra Ab | New pharmaceutical preparation |
| JPH08165244A (ja) * | 1994-10-12 | 1996-06-25 | Taisho Pharmaceut Co Ltd | 皮膚疾患治療剤 |
| ZA96525B (en) * | 1995-02-06 | 1996-08-06 | Astra Ab | Novel pharmaceutical compositions |
| SE504664C2 (sv) * | 1995-09-22 | 1997-03-24 | Scotia Lipidteknik Ab | Sätt att framställa fraktionerad olja, oljan, dess användning samt emulsionskomposition innehållande oljan |
| JP3326059B2 (ja) * | 1995-10-05 | 2002-09-17 | カネボウ株式会社 | 皮膚化粧料 |
-
1998
- 1998-03-06 SE SE9800729A patent/SE9800729L/xx not_active Application Discontinuation
-
1999
- 1999-03-08 WO PCT/SE1999/000347 patent/WO1999044585A1/en not_active Ceased
- 1999-03-08 EP EP99913784A patent/EP1069886B1/en not_active Expired - Lifetime
- 1999-03-08 DE DE69912760T patent/DE69912760T2/de not_active Expired - Lifetime
- 1999-03-08 CA CA002322850A patent/CA2322850A1/en not_active Abandoned
- 1999-03-08 JP JP2000534188A patent/JP2002505272A/ja active Pending
- 1999-03-08 DK DK99913784T patent/DK1069886T3/da active
- 1999-03-08 ES ES99913784T patent/ES2211062T3/es not_active Expired - Lifetime
- 1999-03-08 AU AU31778/99A patent/AU750526B2/en not_active Ceased
- 1999-03-08 PT PT99913784T patent/PT1069886E/pt unknown
- 1999-03-08 AT AT99913784T patent/ATE253895T1/de not_active IP Right Cessation
- 1999-03-08 NZ NZ506756A patent/NZ506756A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005023640A1 (de) * | 2005-05-19 | 2006-11-23 | Beiersdorf Ag | Wirkstoffkombinationen aus Glucosylglyceriden und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und / oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002505272A (ja) | 2002-02-19 |
| CA2322850A1 (en) | 1999-09-10 |
| WO1999044585A1 (en) | 1999-09-10 |
| SE9800729D0 (sv) | 1998-03-06 |
| DK1069886T3 (da) | 2004-03-22 |
| NZ506756A (en) | 2003-10-31 |
| ATE253895T1 (de) | 2003-11-15 |
| AU750526B2 (en) | 2002-07-18 |
| PT1069886E (pt) | 2004-04-30 |
| EP1069886A1 (en) | 2001-01-24 |
| EP1069886B1 (en) | 2003-11-12 |
| ES2211062T3 (es) | 2004-07-01 |
| DE69912760D1 (de) | 2003-12-18 |
| SE9800729L (sv) | 1999-09-07 |
| AU3177899A (en) | 1999-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69912760T2 (de) | Verwendung von topischen formulierungen des öl-in-wasser typs, enthaltend galaktolipid material als emulsionsmittel, um eine länger anhaltende wirkung eines darin enthaltenen aktiven wirkstoffs zu vermitteln | |
| DE69232914T2 (de) | Topische Zubereitung, die eine Suspension von festen lipidischen Teilchen enthält | |
| DE60209213T2 (de) | Lichtdurchlässige Nanoemulsion, ihr Herstellungsverfahren und ihre Verwendungen in der Kosmetik, Dermatologie und/oder Ophthalmologie | |
| DE69500013T2 (de) | Reinigendes Mittel enthaltend lipidische Körner | |
| DE69413867T2 (de) | Mehrfachemulsionen, ihre Herstellung, ihre Verwendung zur Herstellung von kosmetischen Zubereitungen und diese kosmetischen Zubereitungen | |
| DE69400430T2 (de) | Kosmetische und/oder dermatologische Zusammensetzung enthaltend Salicylsäurederivate sowie ihren Verfahren zum Auflösen | |
| DE69400337T2 (de) | Mittel gegen Hautalterung, das gleichzeitig auf die Hautoberschichten und Tiefschichten wirkt | |
| DE69400333T2 (de) | Kosmetische und dermatologische Zusammensetzungen, die eine Kombination aus Ceramiden und Linolsäure enthalten | |
| EP1912624B1 (de) | Wasserfreies mehr-phasen-gel-system | |
| DE4021082C2 (de) | Hautbehandlungsmittel mit hohen Lipidgehalten unter Verwendung eines Bilayer enthaltenden Systems, Salzen organischer Säuren, Alkohol und Stabilisator | |
| DE69500315T2 (de) | Kosmetische oder dermatologische Wasser-in-Öl Emulsion mit hohem Gehalt an Hydroxysäuren | |
| DE602005002844T3 (de) | Umkehremulsionszusammensetzung mit calcitriol und clobetasol-17-propionat und ihre kosmetische und dermatologische verwendung | |
| EP1014916A2 (de) | Schaum-hautschutzcreme | |
| DE69600118T2 (de) | Verwendung der Benzosäurederivate zur Stimulierung die Erneuerung der Epidermis und zur Behandlung der Haut | |
| DE60133038T2 (de) | Hypoallergenisches nichtreizendes hautpflegemittel | |
| WO2023194557A1 (de) | Zusammensetzung zur behandlung der haut | |
| DE4021083A1 (de) | Phospholipidformulierungen und ihre verwendung fuer die zubereitung liposomaler medizinischer und kosmetischer baeder | |
| DE102011110749A1 (de) | Kosmetische oder pharmazeutische Zusammensetzung mit lamellaren Strukturen unter Verwendung von Sucrose-fettsäure-Triestern - einfache und leichte Herstellung | |
| DE19801593A1 (de) | Lipoprotein-Cremes | |
| US20050063930A1 (en) | Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance | |
| DE69904454T2 (de) | Topische formulierungen des öl-in-wasser typs als träger zur vermittlung eines reduzierten reizeffekts | |
| DE69713896T2 (de) | Pharmazeutische formulierungen zur topischen verwendung mit vit. e acetate | |
| DE102005008299B4 (de) | Kosmetische und/oder dermatologische Formulierung, Verfahren zu deren Herstellung und Verwendung der Formulierung | |
| DE60306584T2 (de) | Verwendung eines 7-oxidierten DHEA-Derivats zur Behandlung von trockener Haut | |
| DE60123652T2 (de) | Mikronisierten harnstoff enthaltende wasserfreie hautpflegezusammensezung und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8365 | Fully valid after opposition proceedings |